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Capsule summary:  
• We found a 20% increased risk of atrial fibrillation in patients with hospital-
diagnosed (moderate-to-severe) atopic dermatitis. This finding may be mediated 
through persistent systemic inflammation. 
•  Although the absolute risk is low, the typical early onset of atopic dermatitis 
provides an opportunity for promoting a heart healthy lifestyle in these patients.  
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ABSTRACT   
Background: Atopic dermatitis is characterized by chronic inflammation, which is a 
risk factor for atrial fibrillation.  
Objective: To examine the association between hospital-diagnosed atopic dermatitis 
and atrial fibrillation. 
Methods: Using linked population-based Danish registries, we identified persons with 
an in- or out-patient hospital diagnosis of atopic dermatitis during 1977–2013 and an 
individually-matched comparison cohort. We followed cohorts until death, emigration, 
atrial fibrillation diagnosis or until 2013. We compared 35-year risk of atrial fibrillation 
and estimated hazard ratios with 95% confidence intervals (CIs) using Cox regression, 
adjusting for birth year and sex. We validated 100 atopic dermatitis diagnoses from a 
dermatological department through medical record review. 
Results: We included 13,126 persons with atopic dermatitis and 124,211 comparators 
followed for a median of 19.3 years. The 35-year risk of atrial fibrillation was 0.81% 
and 0.67%, respectively. The positive predictive value of atopic dermatitis diagnoses 
was 99%. The hazard ratio was 1.2 (95% CI: 1.0–1.6) and remained increased after 
adjusting for various atrial fibrillation risk factors.  
Limitations: Limited to moderate-to-severe atopic dermatitis and no lifestyle data. 
Conclusions: Patients with hospital-diagnosed atopic dermatitis have a 20% increased 
long-term risk of atrial fibrillation, but the absolute risk remains low. 
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Capsule summary:  
• We found a 20% increased risk of atrial fibrillation in patients with hospital-
diagnosed (moderate-to-severe) atopic dermatitis. This finding may be mediated 
through persistent systemic inflammation. 
•  Although the absolute risk is low, the typical early onset of atopic dermatitis 
provides an opportunity for promoting a heart healthy lifestyle in these patients. 
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INTRODUCTION 
Atopic dermatitis is a pruritic chronic inflammatory skin disorder.1 Prevalence has 
increased up to three-fold over the last three decades and it now affects 10–20% of 
children in industrialized countries,1 qualifying it as the most common chronic 
childhood disease. However, the common concept that atopic dermatitis is limited to 
childhood is being abolished. Adult-onset atopic dermatitis is more frequent than 
previously appreciated and childhood atopic dermatitis often persist until adulthood or 
may relapse after long periods with inactive disease.1 Thus, up to 10% of adults suffer 
from atopic dermatitis.1  
 Atrial fibrillation is the most commonly sustained rhythm disorder with a 
prevalence of 4% in persons aged 60 years or older.2 It is associated with severe 
morbidity and mortality from e.g. stroke.2 Inflammation is a recognized risk factor for 
atrial fibrillation, as supported by an increased occurrence in patients with rheumatoid 
arthritis and elevated levels of inflammatory biomarkers.3-5 Atopic dermatitis may thus 
predispose to atrial fibrillation due to persistent low-grade systemic inflammation 
and/or increased prevalence of atrial fibrillation risk factors, e.g., obesity, hypertension 
and diabetes.2,6-10  
 To add evidence on this sparsely examined hypothesis,9 we conducted a 
nationwide population-based 35-year cohort study to examine whether patients with 
hospital-diagnosed (moderate-to-severe) atopic dermatitis are at long-term increased 
risk of atrial fibrillation. 
 
METHODS 
Study population 
We used the Danish National Patient Registry (DNPR) to identify individuals born in 
Denmark between 1 January 1947 and 1 January 1983 (approximately 2.7 million) who 
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received a first-time hospital diagnosis of atopic dermatitis from 1 January 1977 until 1 
January 2013.11 At each hospital discharge or outpatient visit, one primary diagnosis 
and optional secondary diagnoses are recorded by the physician in charge using the 
International Classification of Diseases, 8th revision (ICD-8) until the end of 1993 and 
the 10th revision (ICD-10) thereafter. We considered all inpatient, outpatient and 
emergency room diagnoses of atopic dermatitis, using the date of admission or start of 
outpatient follow-up as the ‘index date’. Table 1 shows definitions for study variables. 
We used the Civil Registration System12 to sample a comparison cohort including 
10 individuals from the general population matched to each atopic dermatitis patient by 
sex and birth year. We assigned persons in the comparison cohort with the same index 
date as their corresponding atopic dermatitis patient. 
 
Validation 
We examined the validity of 100 randomly selected inpatient and outpatient diagnoses 
of atopic dermatitis from the Department of Dermatology, Aarhus University Hospital 
during 1977 to 2016. One author (JLR) scrutinized patients’ medical records, using as 
reference standard the diagnosis stated by the treating physician in the medical record.  
 
Atrial fibrillation or flutter 
We used the DNPR to obtain information on all inpatient or outpatient primary or 
secondary diagnoses of atrial fibrillation in the study population. Because of 
overlapping pathophysiology, we included both atrial fibrillation and flutter.13,14 To 
ensure that only incident diagnoses were considered, we excluded persons in the study 
cohorts who had atrial fibrillation recorded before index date.  
 
Patient characteristics  
  7 
We considered patients to have ‘severe atopic dermatitis’ if they filled a prescription for 
azathioprine, cyclosporine, mycophenolate, or methotrexate, which are used in systemic 
atopic dermatitis treatment,1 or if they were admitted with atopic dermatitis coded as 
the primary reason for admission. We identified systemic treatments through the 
Danish National Prescription Registry, which was established in 1995 and includes 
records of all prescription drugs dispensed at Danish pharmacies, classified according 
to the Anatomical Therapeutic Chemical Classification.15 As we were limited to 
patients diagnosed in the hospital-based setting, we considered patients to have at least 
moderate severity at outset. We included severity as a time-updated variable, i.e., 
patients contributed person-time in the moderate category switching to the severe 
category for the remainder of the follow-up if and when they fulfilled the definition for 
severe atopic dermatitis. As an alternative measure of severity and activity, we used 
number of atopic dermatitis contacts (1, 2–4, 5–7, 8 or more). In this analysis, the index 
date was the first, second, fifth and eighth contact, respectively, for atopic dermatitis 
patients and their matched comparators. We also included diagnoses of allergic asthma 
or rhinitis as a measure of atopic multimorbidity. 
 We used the DNPR to identify the following potential atrial fibrillation risk 
factors:2,4,8 chronic obstructive pulmonary disease (COPD), cardiovascular disease 
(ischemic heart disease, heart failure, hypertension, and structural valve problems), 
rheumatic disease, sleep apnea, hospital-diagnosed obesity, hyperthyroidism, chronic 
kidney disease, diabetes, and alcohol-related disease. We used the DNPR11 and Danish 
National Prescription Registry15 to identify procedures and treatment as disease proxies 
to increase completeness when relevant (e.g., antidiabetic drugs as a proxy for 
diabetes). We included these conditions as they could be more prevalent among atopic 
dermatitis patients because of immune-dysregulation, shared pathophysiology, adverse 
effects of treatment, or affected lifestyle choices,1,6,7,9 thereby explaining an association 
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with atrial fibrillation. In the main analysis, we considered the covariables as potential 
confounders, including records available before index date. In additional analyses, we 
added the possibility that they could be mediators by time-updating variables with 
information recorded after start of follow-up. Thus, a person was considered to have a 
given disease from the first registry record defining that disease and onwards.  
 We used education registries from Statistics Denmark16 to identify the highest 
educational level on the index date, classified as short-term (7–10 years), medium-term 
(11–12 years), or long-term (13+ year) education.  
 
Statistical analysis  
For the validation sample, we computed the positive predictive value with 95% 
confidence intervals (based on Wilson’s score method17) as the proportion of confirmed 
diagnoses.  
 We followed cohorts from the index date until atrial fibrillation diagnosis, 
emigration, death, or 1 January 2013, whichever occurred first. We produced 
descriptive statistics for the cohorts. We plotted the cumulative incidence of atrial 
fibrillation for atopic dermatitis and comparison cohorts, with death as a competing 
risk. We used Cox proportional-hazards regression stratified on matched set to compute 
hazard ratios (HRs) with 95% confidence intervals, as a measure of the relative risk of 
the association between atopic dermatitis and atrial fibrillation or flutter. We used time 
from index date as the underlying time scale. To explore the role of certain variables as 
mediators, we fitted several regression models of increasing complexity. Model 1 was 
unadjusted, accounting only for matched factors. Model 2 adjusted additionally for 
baseline atrial fibrillation risk factors. Model 3 adjusted also for educational level for 
those with non-missing information for this variable (i.e., a complete case analysis).  
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 In stratified analyses, we examined whether the association varied by sex and 
presence of allergic asthma or rhinitis. We also examined results for subgroups defined 
by age at first atopic dermatitis contact (0–19, 20–39, 40+ years), severity, and number 
of atopic dermatitis hospital contacts. We performed severity analyses with delayed 
entry until 1 January 1996 to ensure at least 1 year of prescription history.15  
 We performed three sensitivity analyses. We repeated model 2 with atrial 
fibrillation risk factors included as time-updated covariates (mediation analysis). We 
repeated the main analyses with delayed entry until 1 January 1996 in all comparisons. 
We repeated severity analyses adding phototherapy as another criterion for severe 
atopic dermatitis.  
 We verified the assumption of proportional hazards by visual inspection of plots 
of the log(-log(survival)) vs. log(survival time). Analyses were performed with Stata® 
14.2 (StataCorp LP, Texas, US).  
 
RESULTS 
We were able to retrieve all but one medical records for the validation sample. Medical 
review confirmed 98/99 diagnoses, yielding a positive predictive value of 99% (95% 
CI: 95%–100%). 
 We identified 13,144 eligible persons with atopic dermatitis and 124,487 matched 
comparators, subsequently excluding 18 atopic dermatitis patients (together with 165 
comparators) and 111 comparators with prevalent atrial fibrillation. Distribution of 
characteristics was quite similar among atopic dermatitis patients and comparators 
(Table 2). Males accounted for 43%. Median age was 19 years (interquartile range: 6–
29). Allergic asthma or rhinitis and COPD were more common in atopic dermatitis 
patients.  
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 Median follow-up was 19.3 years (total 2,787,675 person-years). The cumulative 
incidence proportion of atrial fibrillation after 35 years of follow-up was 0.81% in the 
atopic dermatitis cohort and 0.67% in the comparison cohort (Figure 1). The 
corresponding unadjusted HR was 1.2 (95% CI: 1.0–1.6) for atopic dermatitis patients 
vs. the matched comparison cohort (Table 3). Increasing level of adjustment had no 
substantial effect on estimates (HRs 1.2 [95% CI: 0.9–1.5]).  
 We found some evidence of variation by sex (HR 1.6 for females vs. 1.0 for 
males), diagnosis age (HR 1.6 for 0–19 years vs. 1.0–1.1 for older age groups), 
coexisting diagnosis of allergic asthma/rhinitis (HR 1.7 for presence vs 1.0 for absence 
of diagnosis), and number of atopic dermatitis contacts for exposed (HR 4.0 for >8 
contacts vs. 1.0 for <2 contacts) (Table 3). The HR was 1.1 (95% CI: 0.8–1.6) for 
moderate and 1.3 (95% CI: 0.9–1.8) for severe atopic dermatitis. These potential 
differences were also apparent on the absolute scale comparing unadjusted rates (Table 
3). 
 Estimates were attenuated, but remained increased, in the mediation analysis 
incorporating time-update for covariables (Table 4). There were no substantial changes 
in estimates when analyzing with delayed entry or when using phototherapy as a proxy 
for severe atopic dermatitis in addition to other systematic therapies and admissions 
(Table 4). 
 
DISCUSSION 
This long-term follow-up study shows evidence that hospital-diagnosed atopic 
dermatitis is associated with a 20% increased relative risk of atrial fibrillation. 
Characteristics associated with particular high risk estimates were female sex, young 
age at first hospital diagnosis, and indicators for severe disease (atopic multimorbidity, 
frequent hospital contact).  
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 To our knowledge, only one previous epidemiologic study has examined this 
topic.9 In a population-based UK cohort study adult persons with versus without atopic 
dermatitis had an HR for atrial fibrillation of 1.11 (99% confidence interval [CI]: 1.04 
to 1.18), increasing to 1.17 (99% CI 1.08–1.27) for moderate and 1.38 (99% CI: 1.17 to 
1.62) for severe disease.9 There was no evidence that age, sex or asthma modified the 
association. Although their study was limited adults and had a median follow-up of 
only 5.1 years, our results are in accordance with findings for moderate-to-severe 
disease. Similarly, adjustment for potential mediators of the association, explained 
findings only partly.  
A potential mechanisms underlying the observed association is systemic 
inflammation, similar to that presumed to link psoriasis and rheumatic disorders to 
atrial fibrillation.3-5,18 Arrhythmogenic effects of atopic dermatitis treatments is also 
possible, although evidence for such adverse effects is limited.19-22 The more 
pronounced association for those with many hospital contacts and coexisting atopic 
conditions supports these mechanisms. Study size precluded analyses of the impact of 
individual systemic drugs for atopic dermatitis. Psychosocial factors and unhealthy 
lifestyle resulting from atopic dermatitis, e.g., stress, elevated blood pressure, smoking, 
diabetes, and hypercholesterolemia, could play a role as well,6,7 although obesity is not 
more prevalent in European patients with atopic dermatitis.10 The slight attenuation 
from adjustment for various atrial fibrillation risk factors could support this hypothesis.  
 The population-based design in a universal healthcare system with virtually 
complete follow-up of patients eliminates selection bias in our study.12 Furthermore, 
follow-up was longer than the UK study (median 19.3 vs. 5.1 years).9 Nevertheless, the 
highest possible attained age was between 30 and 65 years, which is relatively low 
considering the usual age of onset of atrial fibrillation.23 Furthermore, some patients 
may have had atopic dermatitis before entering our study. Because of such onset 
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misclassification, atrial fibrillation risk factors recorded at baseline may be intermediate 
steps (rather than confounders) linking atopic dermatitis to atrial fibrillation. 
 The validity of atopic dermatitis diagnoses was found high in our validation 
sample at a single dermatology department. Although the positive predictive value may 
be unrepresentative of other departments, misclassification of atopic dermatitis in the 
entire study population is unlikely to depend on the outcome (atrial fibrillation) as data 
were prospectively collected. Such non-differential misclassification tends to produce 
underestimates and can therefore not explain an observed association. Furthermore, 
although some patients may actually have had other cutaneous conditions associated 
with atrial fibrillation (e.g., venous insufficiency or pruritus in chronic kidney disease), 
these conditions are rare in young persons, who in our study predominated (50% were 
<20 years at index diagnosis) and had the HR of atrial fibrillation associated with atopic 
dermatitis.  
 Limited variation by severity may result from misclassification, as we lacked 
clinical information on severity or activity. Furthermore, we defined severe disease by 
systemic treatments, which could oppose the proposed mechanism by decreasing 
inflammation and thus lead to underestimates for the severe category in our study. 
Finally, as most patients with atopic dermatitis are diagnosed outside the hospital 
setting, our study already represents the most severe end of the disease spectrum. This 
incompleteness may have affected the possibility to detect variation by severity and 
potential generalizability to mild atopic dermatitis.  
 The positive predictive value of atrial fibrillation diagnoses in the DNPR is high 
(92–99%).24-27 We did not distinguish between atrial fibrillation patterns (paroxysmal, 
persistent, or permanent) or between atrial fibrillation and flutter. As atrial fibrillation 
accounts for >90% of patients registered with these codes,26 our results are likely driven 
by this arrhythmia. Still, as atrial fibrillation and flutter share risk factors and to some 
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degree pathophysiology,13,14 we expect the results to apply to both. Regarding 
completeness, most patients with atrial fibrillation are diagnosed during a hospital 
admission or at a hospital outpatient clinic according to Danish guidelines,28 and very 
few cardiologists work outside the public hospital system in Denmark. However, 
because of regular follow-up of patients with severe atopic dermatitis, opportunity for 
atrial fibrillation diagnosis may be greater than for matched comparators (i.e., 
ascertainment bias). 
 We adjusted for education and several comorbidities, but cannot exclude 
misclassification of these mediators, residual confounding, and confounding from 
unmeasured variables.  
Finally, statistical uncertainty (as measured by width of the confidence intervals) 
should be considered.29 Although our data are best compatible with a 20% increase in 
the rate of atrial fibrillation among atopic dermatitis patients, our data are reasonably 
compatible with a small (10%) decrease to a substantially elevated (50%) increase in 
relative risk. Importantly, subgroup analyses should be interpreted cautiously as the 
lower number of events reduce the statistical precision. 
 In conclusion, patients with hospital-diagnosed (moderate-to-severe) atopic 
dermatitis have a 20% increased long-term risk of atrial fibrillation compared with the 
general population. Although the clinical implications are limited by a low absolute risk 
of atrial fibrillation, the typical early onset of atopic dermatitis may provide clinicians 
with a unique opportunity for promoting a heart healthy lifestyle to reduce risk for 
cardiovascular disease, including atrial fibrillation. 
 
Contributions: MS and MO conceived the study idea and designed the study. MO and 
JLR established and designed the cohort. SAJS had full access to all of the data in the 
study and takes responsibility for the integrity of the data and the accuracy of the data 
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analysis. All authors participated in the discussion and interpretation of the results. 
SAJS organized the writing and wrote the initial drafts. All authors critically revised the 
manuscript for intellectual content and approved the final version.  
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Figure 1. Risk of atrial fibrillation or flutter in patients with hospital-diagnosed atopic 
dermatitis and a matched comparison cohort, adjusted for birth year and sex, Denmark, 
1977–2013 
  19 
Table 1. Registry codes used to identify study variables1 
Variable Code(s) 
Atopic dermatitis ICD-8: 691; 
ICD-10: L20; 
Azathioprine ATC code: L04AX01; 
Procedure code: BWHB83 
Methotrexate ATC code: L01BA01, L04AX03; 
Procedure code: BWHA115  
Cyclosporine ATC code: L04AD01; 
Procedure code: BOHJ20 
Mycophenolate ATC code: L04AA06; 
Procedure code: BOHJ22 
Phototherapy Procedure code: BNGA1, BNGA2, BNGA3, BNGA4 
Atrial fibrillation and 
flutter 
ICD-8: 42793, 42794; 
ICD-10: I48; 
Allergic asthma ICD-8: 493; 
ICD-10: J450; 
Allergic rhinitis ICD-8: 50709; 
ICD-10: J301–J304; 
Chronic obstructive 
pulmonary disease or 
non-allergic asthma. 
ICD-8: 491, 492; 
ICD-10: J41, J42, J43, J44, J45 (except J450), J46; 
ATC code: R03 (at least two prescriptions) except if the 
person has a prevalent allergic asthma diagnosis 
Cardiovascular 
disease, including 
structural valve 
problems, 
hypertension, 
ischemic heart 
disease, and heart 
failure 
ICD-8: 393-398, 400-404, 410-414, 425, 42709, 42710, 
42711, 42719, 78249; 
ICD-10: I05-I09, I10-I15, I20-I25, I34-I37, I390, I393, I42 
(excl. I426 included below), I43, I50, I511A, Q22; 
ATC code: C01DA, C02, C03,   
C07, C08, C09, B01AC04, B01AC06, N02BA01;  
Procedure code: 30009, 30019, 30029, 30039, 30049, 
30059, 30069, 30079, 30089, 30099, 30109, 30119, 30120, 
30129, 30139, 30149, 30159, 30169, 30179, 30189, 30199, 
30200 30300, 30310, 30320, 30330, 30340, 30350, 30360, 
30600, 30620, 30640, 30660, 30700, 30701, 30709, 30719, 
30720, 30729, 30740, 30780, 30799, 30800, 30810, 30910, 
30920, 30925, 30939, 30959, 30990, 31100, 31101, 31119, 
31129, 31130, 31180, 31199, 31200, 31210, 31220, 31229, 
31230, 31249, 31259, 31268, 31269, 31280, 31299, 31310, 
30350, 30354, 30240, KFNA-E, KFNH20, KFM (excluding 
KFMA32, KFMD10-14, KFMH10), KFK (excluding 
KFKA32, KFKC70, KFKH10), KFG (excluding KFGA32) 
KFJE (excluding KFJE42), KFJF, KFJW, KFNG, KFNF  
Rheumatic disease ICD-8: 28709, 69609, 712, 716, 734, 446; 
ICD-10: D690B, G737, G058A, H221B, I328A, I328B, 
I398C, I398E, I418A, I528A, I776, L931, L932, L95, M05-
M07, M30–M36, M45, M793, N085, N164; 
Sleep apnea ICD-10: G473 
Obesity ICD-8: 277; 
ICD-10: E65-E66; 
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Hyperthyroidism ICD-8: 242; 
ICD-10: E05, H062, E060, E062; 
ATC code: H03B 
Chronic kidney 
disease 
ICD-8: 584, 792, 9977, Y9509; 
ICD-10: L298C, G638A, E853B, T825A, T825B, T825C, 
T856C, I120, I131, I132, I770, N165, N180, N183, N184, 
N185, N188, N189, N19, T824, T861, Z49, Z94, Z992, 
T817E1; 
Procedure code: KJAK10, KJAK11, KJAK13, KJAK14, 
KTJA30, KTJA32, KTJA35, KKAS, BJFD2, BJFZ, BJKB, 
BUFC1, BWDC5, ZZ0151A, ZZ4341, ZZ4342, ZZ4343, 
ZZ4346, ZZ4347, ZZ4348, ZZ4350, 57480, 57490, 87409, 
87419, 87420, 87430, 87431, 87432, 87440, 92390, 92400, 
94300, 94340 
Diabetes mellitus ICD-8: 249-250;  
ICD-10: E10-E14, H360, O24 (except O244), H360, N083, 
DG632; 
ATC code: A10 
Alcoholism-related 
disorder or 
prescription 
 
ICD-8: 291, 303, 57109-57110, 57710, 979, 980; 
ICD-10: F10, G312, G621, G721, I426, K292, K700, K703, 
K860, R780, T510, T519, Z721; 
ATC code: N07BB01 
ICD: International Classification of Diseases; ATC: Anatomical Therapeutic Chemical 
1Only primary and secondary diagnoses are included from the Danish National Patient 
Registry 
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Table 2. Characteristics at cohort entry for persons with hospital-diagnosed atopic 
dermatitis compared with a matched comparison cohort, Denmark, 1977–2013 
Atopic dermatitis Matched comparators 
No. % No. % 
Total 13126 100 124211 100 
Sex 
Male 5630 43 54024 43 
Female 7496 57 70187 57 
Birth year 
1947–1956 1266 10 11800 9 
1957–1966 2631 20 24525 20 
1967–1982 9229 70 87886 71 
Age at start of follow-up     
0–19 6509 50 64274 52 
20–39 5208 40 47165 38 
40–63 1409 11 12772 10 
Allergic asthma or rhinitis 842 6 1002 1 
Sleep apnea 6 0 54 0 
Hospital-diagnosed obesity 88 1 835 1 
Rheumatic disease 110 1 498 0 
Chronic kidney disease 35 0 87 0 
COPD 1536 12 5648 5 
Cardiovascular disease 459 3 3149 3 
Diabetes mellitus 84 1 771 1 
Hyperthyroidism 32 0 325 0 
Alcohol-related disease 243 2 1681 1 
Educational level     
Short term education 2608 20 23380 19 
Medium term education 5172 39 53272 43 
Long term education 5109 39 45512 37 
Missing 237 2 2047 2 
All variables in the table are measured at start of follow-up
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Table 3. Observations, events, person-years, rates and hazard ratios of atrial fibrillation or flutter for persons with hospital-diagnosed atopic 
dermatitis compared with a matched comparison cohort, Denmark, 1977-2013 
Observations Events Person-years 
Rate (per 
100000) 
Model 1 
(unadjusted)1 
Model 2 (+atrial 
fibrillation risk 
factors)2 
Model 3 
(+educational 
level)3 
Overall 
Comparators 124211 631 2530240 24.9 1 (reference) 1 (reference) 1 (reference) 
Atopic dermatitis 13126 80 257435 31.1 1.2 (1.0–1.6) 1.2 (0.9–1.5) 1.2 (0.9–1.5) 
Sex 
Males 
Comparators 54024 402 1188398 33.8 1 (reference) 1 (reference) 1 (reference) 
Atopic dermatitis 5630 43 119291 36.0 1.0 (0.7–1.4) 1.0 (0.7–1.3) 1.0 (0.7–1.4) 
Females 
Comparators 70187 229 1341842 17.1 1 (reference) 1 (reference) 1 (reference) 
Atopic dermatitis 7496 37 138143 26.8 1.6 (1.1–2.3) 1.6 (1.1–2.3) 1.6 (1.1–2.3) 
Age at start of follow-up 
0–19 years 
Comparators 64274 190 1716596 11.1 1 (reference) 1 (reference) 1 (reference) 
Atopic dermatitis 6509 29 170203 17.0 1.6 (1.1–2.4) 1.6 (1.1–2.4) 1.6 (1.1–2.4) 
20–39 years 
Comparators 47165 253 698660 36.2 1 (reference) 1 (reference) 1 (reference) 
Atopic dermatitis 5208 28 74928 37.4 1.0 (0.7–1.6) 1.0 (0.7–1.5) 1.0 (0.7–1.5) 
40–63 years 
Comparators 12772 188 114984 163.5 1 (reference) 1 (reference) 1 (reference) 
Atopic dermatitis 1409 23 12304 186.9 1.1 (0.7–1.8) 1.1 (0.7–1.7) 1.1 (0.7–1.7) 
Severity 
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Moderate 
Comparators 76169 300 911576 32.9 1 (reference) 1 (reference) 1 (reference) 
Atopic dermatitis 8357 38 98463 38.6 1.2 (0.8–1.7) 1.1 (0.8–1.6) 1.1 (0.8–1.6) 
Severe 
Comparators 45873 280 637486 43.9 1 (reference) 1 (reference) 1 (reference) 
Atopic dermatitis 5023 39 69348 56.2 1.3 (0.9–1.8) 1.2 (0.9–1.8) 1.3 (0.9–1.8) 
Allergic asthma/rhinitis 
No 
Comparators 94260 435 1669224 26.1 1 (reference) 1 (reference) 1 (reference) 
Atopic dermatitis 9979 47 170487 27.6 1.0 (0.8–1.4) 1.0 (0.7–1.4) 1.0 (0.7–1.4) 
Yes 
Comparators 41472 196 861016 22.8 1 (reference) 1 (reference) 1 (reference) 
Atopic dermatitis 4347 33 86948 38.0 1.7 (1.2–2.5) 1.6 (1.1–2.4) 1.7 (1.1–2.4) 
Number of atopic dermatitis contacts 
1 contact 
Comparators 124211 417 1787221 23.3 1 (reference) 1 (reference) 1 (reference) 
Atopic dermatitis 13126 45 182210 24.7 1.0 (0.8–1.4) 1.0 (0.8–1.4) 1.0 (0.8–1.4) 
2–4 contacts 
Comparators 40452 162 619928 26.1 1 (reference) 1 (reference) 1 (reference) 
Atopic dermatitis 4277 27 62925 42.9 1.6 (1.1–2.5) 1.6 (1.0–2.4) 1.6 (1.0–2.4) 
5–7 contacts 
Comparators 7653 37 79909 46.3 1 (reference) 1 (reference) 1 (reference) 
Atopic dermatitis 806 3 7964 37.7 0.7 (0.2–2.4) 0.8 (0.3–2.8) 0.9 (0.3–2.8) 
8+ contacts 
Comparators 3052 15 43182 34.7 1 (reference) 1 (reference) 1 (reference) 
Atopic dermatitis 327 5 4336 115.3 3.2 (1.1–8.8) 3.9 (1.3–12.0) 4.0 (1.3–12.6) 
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1Stratified by matched set to account for matching factors (birth year, sex, index date). 
2Additionally adjusted for baseline chronic obstructive pulmonary disease, cardiovascular disease, rheumatic disease, sleep apnea, hospital-
diagnosed obesity, hyperthyroidism, chronic kidney disease, diabetes mellitus, and alcohol-related disease.  
3Additionally adjusted for educational level (complete-case analysis). 
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Table 4. Hazard ratios (95% CIs)1 of atrial fibrillation or flutter for persons with hospital-diagnosed atopic dermatitis compared with a matched 
comparison cohort, Denmark, 1977–2013. Sensitivity analyses. 
 Sensitivity analysis 12 Sensitivity analysis 23 Sensitivity analysis 34 
Model 2  Model 1 Model 2 Model 3 Model 1 Model 2 Model 3 
Overall 1.0 (0.8–1.3) 1.2 (1.0–1.6) 1.2 (0.9–1.5) 1.2 (0.9–1.5) NA NA NA 
Sex       
Male 0.9 (0.6–1.2) 1.0 (0.7–1.4) 1.0 (0.7–1.3) 1.0 (0.7–1.3) NA NA NA 
Female 1.5 (1.0–2.1) 1.6 (1.1–2.3) 1.6 (1.1–2.3) 1.6 (1.1–2.3) NA NA NA 
Diagnosis age        
0–19 1.5 (1.0–2.4) 1.5 (1.0–2.3) 1.5 (1.0–2.3) 1.5 (1.0–2.3) NA NA NA 
20–39 0.9 (0.6–1.3) 1.1 (0.7–1.6) 1.0 (0.7–1.5) 1.0 (0.7–1.6) NA NA NA 
40–63 0.9 (0.6–1.5) 1.1 (0.7–1.8) 1.1 (0.7–1.7) 1.1 (0.7–1.7) NA NA NA 
Severity        
Moderate 1.1 (0.7–1.5) 1.2 (0.8–1.7) 1.1 (0.8–1.6) 1.1 (0.8–1.6) 1.2 (0.9–1.7) 1.2 (0.8–1.7) 1.2 (0.8–1.7) 
Severe 1.1 (0.7–1.5) 1.3 (0.9–1.8) 1.2 (0.9–1.8) 1.3 (0.9–1.8) 1.2 (0.9–1.7) 1.2 (0.9–1.7) 1.2 (0.9–1.7) 
Allergic asthma/rhinitis 
No 0.9 (0.7–1.2) 1.0 (0.8–1.4) 1.0 (0.7–1.4) 1.0 (0.7–1.4) NA NA NA 
Yes 1.4 (0.9–2.2) 1.7 (1.1–2.4) 1.6 (1.1–2.4) 1.6 (1.1–2.4) NA NA NA 
Number atopic dermatitis of contacts 
<2 contacts 0.9 (0.7–1.3) 1.1 (0.8–1.5) 1.0 (0.8–1.4) 1.1 (0.8–1.4) NA NA NA 
2–4 contacts 1.3 (0.8–2.0) 1.6 (1.1–2.5) 1.5 (1.0–2.4) 1.5 (1.0–2.4) NA NA NA 
5–7 contacts 1.1 (0.3–4.4) 0.5 (0.1–2.1) 0.6 (0.1–2.4) 0.6 (0.1–2.5) NA NA NA 
8+ contacts 2.9 (0.6–14.1) 3.2 (1.1–8.8) 3.9 (1.3–12.0) 4.0 (1.3–12.6) NA NA NA 
1Based on a Cox regression model stratified by matched set to account for matching factors (birth year, sex, index date). Model 1 was 
unadjusted. Model 2 additionally adjusted for chronic obstructive pulmonary disease, cardiovascular disease, rheumatic disease, sleep apnea, 
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hospital-diagnosed obesity, hyperthyroidism, chronic kidney disease, diabetes mellitus, and alcohol-related disease. Model 3 additionally 
adjusted for educational level (complete-case analysis). 
2Repeated model 2 with atrial fibrillation risk factors included as time-updated covariates (mediation analysis) 
3Repeated the main analyses with delayed entry until 1 January 1996 in all comparisons 
4Repeated severity analyses adding phototherapy as another criterion for severe atopic dermatitis. 
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